March 8th 2024
On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.
Maternal Study Satisfaction Increases Visit Compliance in Children at Risk for Diabetes
Maternal characteristics, sociodemographic factors, and paternal participation during the initial year of the TEDDY study were identified as key predictors of enhanced visit compliance in a pediatric cohort genetically predisposed to type 1 diabetes.
Maternal Height, Pre-Pregnancy BMI, Weight Gain Affect Adverse Pregnancy Events
December 19th 2023Maternal height is linked to specific adverse pregnancy events in women with gestational diabetes mellitus, according to a new study. The investigators found shorter women had higher rates of low birth rate and primary c-sections, but taller women had higher rates of abnormal neonatal ponderal index, postpartum hemorrhage, and macrosomia.
Psychosocial Outcome Improvement Observed in Diabetes Patients Using Automated Insulin Delivery
Addressing a lack of quantitative data on AID, this study used validated measures in a real-world setting to corroborate the psychosocial benefits seen in prior qualitative research.
Tighter Versus Less-Tight Glycemic Treatment Compares Similarly for Gestational Diabetes Mellitus
December 19th 2023Tight glycemic target treatment compares similarly to less-tight glycemic target treatment in terms of how it affects the mental health status of women with gestational diabetes mellitus.
FIDELITY Analysis Details Benefits of Early Albuminuria Reduction in CKD
November 2nd 2023Rajiv Agarwal, MD, MS, provides insight into an analysis from ASN Kidney Week 2023 detailing the effect of early albuminuria reduction on risk of adverse kidney and cardiovascular outcomes in people with T2D and chronic kidney disease.
Racial Disparities in Diabetes Management Go Beyond Insurance Status, Study Finds
October 17th 2023Despite access to care and health insurance, Hispanic and non-Hispanic Black individuals with diabetes experience poorer glycemic control compared to non-Hispanic White counterparts, revealing persistent racial disparities in healthcare.
Novo Nordisk Halts Semaglutide Kidney Outcomes Trial for Early Efficacy
October 11th 2023On October 10, 2023, Novo Nordisk announced they would be stopping the FLOW trial, which examined the effects of semaglutide 1.0 mg on kidney outcomes in type 2 diabetes, due to early efficacy based on an interim analysis of the trial.